Log in or Sign up for Free to view tailored content for your specialty!
Neuroendocrinology News
Neuroendocrine tumors require individualized treatment approach
Patients with neuroendocrine tumors are at greater risk for cancer-associated death compared with death due to other causes; however, mortality rates vary according to tumor site.
Dentists, orthodontists play key role in recognizing facial manifestations of acromegaly
Dentists and orthodontists are uniquely positioned to identify the early facial manifestations of acromegaly, though new survey data suggest more awareness of the condition is needed to improve early diagnoses.
Log in or Sign up for Free to view tailored content for your specialty!
FDA approves first once-weekly injection for pediatric GH deficiency
The FDA approved the first once-weekly formulation of somatropin for children with growth hormone deficiency, according to an industry press release.
ACROSTUDY: Pegvisomant safe, effective for long-term use in acromegaly
Real-world data from the long-term ACROSTUDY show the growth hormone receptor agonist pegvisomant is safe and effective, with a low incidence of liver enzyme elevation and no increase in tumor size for most patients with acromegaly.
Experts offer recommendations for management of pituitary tumors
An international panel reached consensus for pre- and postoperative endocrine testing to manage adults undergoing transsphenoidal surgery, including measurement of prolactin and insulin-like growth factor I levels for all pituitary tumors.
Oral octreotide associated with better quality of life, work productivity in acromegaly
Adults with acromegaly reported improved quality of life and more work productivity after transitioning from injectable somatostatin receptor ligands to oral octreotide capsules, according to MPOWERED phase 3 trial data.
FDA accepts NDA for novel Cushing’s syndrome treatment
The FDA accepted for review a new drug application for the steroidogenesis inhibitor levoketoconazole for the treatment of endogenous Cushing’s syndrome, according to an industry press release.
Oral octreotide provides sustained biochemical control in acromegaly
Adults with acromegaly who responded to treatment with an oral form of the somatostatin analogue octreotide maintained response for an additional 48 weeks with no new safety signals observed, data from an open-label extension study show.
Cancer rate not elevated for adults with acromegaly
Adults treated for acromegaly at a medical center in Turkey do not have an increased risk for cancer compared with the general population, according to study findings published in Endocrine Practice.
Thyroid dysfunction highly prevalent in Cushing’s syndrome
Central hypothyroidism is prevalent in about 1 in 2 adults with Cushing’s syndrome, and thyroid function can be restored after curative surgery for most patients, according to study findings.
-
Headline News
A potential new paradigm for treating acute migraine: Timolol nasal spray
November 15, 20245 min read -
Headline News
AI-enabled video of skin on face, hands may detect high blood pressure, diabetes
November 15, 20242 min read -
Headline News
‘Troubling’ data show lack of awareness about lung cancer screening
November 15, 20242 min read
-
Headline News
A potential new paradigm for treating acute migraine: Timolol nasal spray
November 15, 20245 min read -
Headline News
AI-enabled video of skin on face, hands may detect high blood pressure, diabetes
November 15, 20242 min read -
Headline News
‘Troubling’ data show lack of awareness about lung cancer screening
November 15, 20242 min read